Ongoing research aims to improve the efficacy and safety profile of CTLA-4 inhibitors. Scientists are exploring combination therapies, dosing strategies, and identifying biomarkers that can predict which patients are most likely to benefit from treatment. Additionally, new generations of immune checkpoint inhibitors are being developed to target multiple pathways simultaneously, potentially offering more comprehensive and effective cancer treatments.
